MIRA INFORM REPORT

 

 

Report Date :

10.05.2014

 

IDENTIFICATION DETAILS

 

Name :

HANGZHOU VERYCHEM SCIENCE AND TECHNOLOGY CO., LTD.

 

 

Registered Office :

F-1003 Jianqiao Gongshe, No. 753 Shenhua Road, Xihu District, Hangzhou, Zhejiang Province 310030 Pr

 

 

Country :

China

 

 

Date of Incorporation :

15.04.2004

 

 

Com. Reg. No.:

330105000070519

 

 

Legal Form :

Limited Liabilities Company

 

 

Line of Business :

selling of pharmaceutical and chemical products

 

 

No. of Employees :

06

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

TATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but Correct  

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31, 2014

 

Country Name

Previous Rating

(31.12.2013)

Current Rating

(31.03.2014)

China

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderately Low Risk

 

B1

Moderate Risk

 

B2

Moderately  High Risk

C1

High Risk

 

C2

Very High Risk

 

D


 

 

china ECONOMIC OVERVIEW

 

Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation and expanded the daily trading band within which the RMB is permitted to fluctuate. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2013 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. Several factors are converging to slow China's growth, including debt overhang from its credit-fueled stimulus program, industrial overcapacity, inefficient allocation of capital by state-owned banks, and the slow recovery of China's trading partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated at the Communist Party's "Third Plenum" meeting in November 2013, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent in the future on fixed investments, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. The new government of President XI Jinping has signaled a greater willingness to undertake reforms that focus on China's long-term economic health, including giving the market a more decisive role in allocating resources

Source : CIA

 

 

 

 

 


Company name & address

 

Hangzhou Verychem Science And Technology Co., Ltd.

F-1003 jianqiao gongshe, no. 753 Shenhua Road

xihu district, hangzhou, zhejiang province 310030 PR CHINA

TEL: 86 (0) 571-88162785/88162786/85161836

FAX: 86 (0) 571-88162787

 

 

EXECUTIVE SUMMARY

 

Date of Registration         : april 15, 2004

REGISTRATION NO.                  : 330105000070519

LEGAL FORM                           : Limited liabilities company

CHIEF EXECUTIVE                   : peng jiafei (LEGAL REPRESENTATIVE)

REGISTERED CAPITAL : cny 500,000

staff                                      : 6

BUSINESS CATEGORY : trading

Revenue                                : n/a (AS OF DEC. 31, 2012)

EQUITIES                                 : n/a (AS OF DEC. 31, 2012)

WEBSITE                                  : www.verychem.com

E-MAIL                                     : service@verychem.com & lucy@verypharm.com

PAYMENT                                : AVERAGE

MARKET CONDITION                : average

FINANCIAL CONDITION             : n/a

OPERATIONAL TREND : ORDINARY

GENERAL REPUTATION           : average

EXCHANGE RATE                    : CNY 6.10 = USD 1

 

Adopted abbreviations (as follows)

SC - Subject Company (the company inquired by you)

N/A – Not available

CNY – China Yuan Ren Min Bi

 

 

OPERATIONAL TREND & GENERAL REPUTATION

 

This section aims at indicating the relative positions of SC in respect of its operational trend & general reputation

 

Operational Trend:-                                            General Reputation:-

Upward                                                             Excellent

Steady                                                              Good

Fairly Steady                                                     Fairly Good

Ordinary                                                            Average

Fair                                                                   Fair

Stagnant                                                           Detrimental

Downward                                                         Not known

Not known                                                         Not yet be determined

 

LEGAL STATUS & HISTORY

 

SC was established as a limited liabilities company of PRC with State Administration of Industry & Commerce (SAIC) under registration No.: 330105000070519 on April 15, 2004.

 

SC’s Organization Code Certificate No.: 75953963-4

 

SC’s Tax No.: 330103759539634

 

SC’s registered capital: cny 500,000

 

SC’s paid-in capital: cny 500,000

 

Registration Change Record:-

 

No significant changes of SC have been noted in SAIC since its incorporation.

 

Current Co search indicates SC’s shareholders & chief executives are as follows:-

 

Name of Shareholder (s)

% of Shareholding

Peng Jiafei

90

Peng Lifei

10

 

SC’s Chief Executives:-

 

Position

Name

Legal Representative, Chairman and General Manager

Peng Jiafei

Supervisor

Peng Lifei

 

 

RECENT DEVELOPMENT

 

No recent development was found during our checks at present.

 

 

SHAREHOLDER CHART & BACKGROUND

 

Name                                                                                      % of Shareholding

Peng Jiafei                                                                                                       90

Peng Lifei                                                                                                         10

 

 

MANAGEMENT

 

Peng Jiafei, Legal Representative, Chairman and General Manager

---------------------------------------------------------------------------------------------------

Ø  Gender: M

Ø  Working experience (s):

 

At present, working in SC as legal representative, chairman and general manager

 

Peng Lifei , Supervisor

-----------------------------------------

Ø  Gender: M

 

 

BUSINESS OPERATION

 

SC’s registered business scope includes technology development, technology consultation, technology services, and fruit transfer for medicine, chemical products, network engineering, and computer software; selling chemical materials & products, computer & components, electronic products, meters & instruments, medical equipment, and general machinery; importing and exporting commodities and technology.

 

SC is mainly engaged in selling pharmaceutical and chemical products.

 

SC’s products mainly include:

 

http://www.verychem.com/images/ar.jpgFluvoxamine Maleate Intermediate

5-Methoxy-1-[4-(Trifluoromethyl)Phenyl]-1-Pentanone   CAS: 61718-80-7

http://www.verychem.com/images/ar.jpgSarpogrelate Hydrochloride intermediate

2-[2-(3-Methoxyphenyl)ethenyl]phenol  CAS: 143212-74-2
2-(2-(3-Methoxy)Phenylethyl)Phenol  CAS: 167145-13-3
2-[[3-(Dimethylamino)-2-Hydroxypropoxy]Phenyl]Ethyl-3-Methoxybenzene Hydrochloride CAS:135261-74-4

http://www.verychem.com/images/ar.jpgIntermediate of Lumefantrine(Benflumetol)

2,7-Dichloro-alpha-[(dibutylamino)methyl]-9H-fluorene-4-methanol CAS: 69759-61-1

http://www.verychem.com/images/ar.jpgOlmesartan Medoxomil Intermediate

Trityl Olmesartan Medoxomil    CAS: 144690-92-6
Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate   CAS: 144689-93-0
5-[4'-(Bromomethyl)[1,1'-Biphenyl]-2-Yl]-2-(Triphenylmethyl)-2H-Tetrazole   CAS: 124750-51-2
1H-Imidazole-4,5-Dicarboxylic Acid, 2-Propyl-, Diethyl Ester   CAS: 144689-94-1
4-Chloromethyl-5-Methyl-1,3-Dioxol-2-One    CAS: 80841-78-7

http://www.verychem.com/images/ar.jpgIntermediate Of Bepotastine Besilate

(4-Chlorophenyl)(2-pyridinyl)methanone CAS: 6318-51-0
2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine CAS: 122368-54-1

http://www.verychem.com/images/ar.jpgIntermediate of Losartan

2-Butyl-5-chloro-1-H-imidazole-4-carbaldehyde CAS: 83857-96-9

http://www.verychem.com/images/ar.jpgIntermediate Of Etizolam

2-Chlorobenzoylacetonitrile CAS: 40018-25-5
2-Amino-3-(2-chlorobenzoyl)-5-ethylthiophene CAS: 50508-60-6

http://www.verychem.com/images/ar.jpgIntermediate Of Sitafloxacin Hydrate

3-Quinolinecarboxylicacid,7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-,hydrate (2:3) CAS:147782-16-9

http://www.verychem.com/images/ar.jpgIntermediate Of Bosentan Hydrate

4-tert-Butyl-N-(6-chloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide potassium salt  
CAS: 301646-59-3
4,6-Dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine CAS: 150728-13-5

http://www.verychem.com/images/ar.jpgIntermediate Of Lafutidine

N-{4-[4-(piperidiomethyl)pyridyl-2-oxy]-cis-2-butene}phthalimide maleic acid  CAS:146447-26-9
4-Nitrophenyl 2-(furfurylsulfinyl)acetic acid   CAS: 123855-55-0

http://www.verychem.com/images/ar.jpgIntermediate Of Olopatadine Hydrochloride

Phosphonium [3-(dimethylamino)propyl]triphenyl bromide hydrobromide   CAS: 27710-82-3
6,11-dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid CAS: 55453-87-7

http://www.verychem.com/images/ar.jpgIntermediate Of Dronedarone hydrochloride

2-Butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran CAS: 141645-16-1
(2-butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone CAS: 141627-42-1
N-Butyl-N-(3-chloropropyl)-1-butanamine CAS: 36421-15-5

http://www.verychem.com/images/ar.jpgIntermediate of Febuxostat

2-[3-cyano-4-(2-methylpropoxy)phenyl]4-methyl-5-Thiazolecarboxylic acid ethyl ester CAS: 160844-75-7
Ethyl 2-(3-bromo-4-isobutoxyphenyl)- 4-methyl-5-thiazolecarboxylate CAS: 144060-96-8
Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate CAS: 161798-01-2

http://www.verychem.com/images/ar.jpgIntermediate Of Paliperidone

3-(2-Chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one  CAS:130049-82-0

http://www.verychem.com/images/ar.jpgIntermediate Of Levosimendan

(R)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone  CAS: 101328-85-2
6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3-(2H)-one  CAS: 36725-28-7

 

SC sources its materials 100% from domestic market. SC sells 65% of its products in domestic market, and 35% to overseas market, mainly Southeast Asia, etc.

 

The buying terms of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.

 

Staff & Office:

--------------------------

SC is known to have approx. 6 staff at present.

 

SC rents an area as its operating office, but the detailed information is unknown.

 

 

RELATED COMPANY

 

SC is not known to have any subsidiary at present.

 

PAYMENT

 

Overall payment appraisal:

( ) Excellent      ( ) Good      (X) Average      ( ) Fair      ( ) Poor      ( ) Not yet be determined

The appraisal serves as a reference to reveal SC's payments habits and ability to pay.  It is based on the 3 weighed factors: Trade payment experience (through current enquiry with SC's suppliers), our delinquent payment and our debt collection record concerning SC.

 

Trade payment experience: SC did not provide any name of trade/service suppliers and we have no other sources to conduct the enquiry at present.

 

Delinquent payment record: None in our database.

 

Debt collection record: No overdue amount owed by SC was placed to us for collection within the last 6 years.

 

 

BANKING

 

The bank information of SC is not filed in local SAIC.

 

 


FINANCIALS

 

SC’s financials are not filed in local SAIC, and SC also refused to release the details.

 

 

CONCLUSIONS

 

SC is considered small-sized in its line with 9 years business history.

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.60.05

UK Pound

1

Rs.101.65

Euro

1

Rs.83.07

 

INFORMATION DETAILS

 

Report Prepared by :

PDT

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.